Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression |
Park, Ha-Young
(Department of Internal Medicine, Chonnam National University Medical School)
Oh, In-Jae (Department of Internal Medicine, Chonnam National University Medical School) Kho, Bo Gun (Department of Internal Medicine, Chonnam National University Medical School) Kim, Tae-Ok (Department of Internal Medicine, Chonnam National University Medical School) Shin, Hong-Joon (Department of Internal Medicine, Chonnam National University Medical School) Park, Cheol Kyu (Department of Internal Medicine, Chonnam National University Medical School) Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Medical School) Kim, Yu-Il (Department of Internal Medicine, Chonnam National University Medical School) Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Medical School) Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Medical School) Choi, Yoo-Duk (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) |
1 | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30. DOI |
2 | Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis 2016;79:58-69. DOI |
3 | Kweon SS. Updates on cancer epidemiology in Korea, 2018. Chonnam Med J 2018;54:90-100. DOI |
4 | Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. DOI |
5 | Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-29. DOI |
6 | Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767-78. DOI |
7 | Chen DS, Irving BA, Hodi FS. Molecular pathways: nextgeneration immunotherapy: inhibiting programmed deathligand 1 and programmed death-1. Clin Cancer Res 2012;18:6580-7. DOI |
8 | Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013;20:22-31. DOI |
9 | Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 2016;4:48. DOI |
10 | Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-56. DOI |
11 | Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PDL1 IHC assay comparison project. J Thorac Oncol 2017;12:208-22. DOI |
12 | Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016;24:392-7. DOI |
13 | Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-8. DOI |
14 | Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015;89:181-8. DOI |
15 | Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014;25:1935-40. DOI |
16 | Adam J, Rouquette I, Damotte D, Badoual C, Danel C, Damiola F, et al. PL04a.04: multicentric French harmonization study for PD-L1 IHC testing in NSCLC. J Thorac Oncol 2017;12(1 Suppl):S11-2. DOI |
17 | Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of nonsmall cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 2016;11:95. DOI |
18 | Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, et al. Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors. J Thorac Oncol 2017;12:1654-63. DOI |
19 | Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16. DOI |
20 | Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016;29:1165-72. DOI |
21 | Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res 2017;23:3585-91. DOI |